bioXcelerate AI

Our mission is to enable our clients to unlock research-driven insights into drug discovery and clinical development. This is made possible through our team of highly skilled data scientists, who leverage their academic knowledge to apply cutting-edge statistics, machine learning, and software engineering.  At our core is the ability to tailor solutions that meet our clients' unique needs and computational infrastructure, all in the pursuit of speeding up the journey to critical healthcare insights.  By skillfully orchestrating our toolkits and expertise, we construct fully bespoke, end-to-end solutions that align precisely with our clients' objectives and empower them to make data-driven decisions with confidence and efficiency.

Content by bioXcelerate AI

Black, female scientist using a microscope for analysis in a healthcare lab
| 2 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
3D illustration of a protein complex composed of clustered spherical subunits arranged in a ring-like oligomeric structure, shown in shades of blue, cyan, and purple against a blue gradient background.
Automated mass photometry helps reveal the complex dynamics of protein oligomerization and the factors that govern protein assembly.
A 3D rendering illustrates a sandwich ELISA technique, where antigen detection is achieved between two layers of antibodies: a capture antibody and a detection antibody
Learn the key characteristics that determine whether an immunoassay generates accurate and reproducible data.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue